BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease

Inozyme Pharma’s main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels. BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications. The post BioMarin’s $270M Inozyme Acquisition…

Read More

American Medicine’s Meagerness Paradox

By MARC-DAVID MUNK In our palliative medicine clinic in the working suburbs of Boston, my colleagues and I tend to some of the sickest patients in the city. Through the window, I can see the afflicted pull up to our squat building in family sedans, wheelchair vans, and subsidized municipal ride cars. Few drive themselves:…

Read More

20% of the economy will be spent on health care by 2033

CMS’s Office of the Actuary predicts that national healthcare expenditures (NHE) will increase from 17.6% of GDP in 2023 to 20.3% of GDP by 2033. The Keehan et al. (2025) paper provides more details: National health expenditures are projected to have grown 8.2 percent in 2024 and to increase 7.1 percent in 2025, reflecting continued…

Read More

Why Providers Aren’t Happy with CMS’ Outpatient Medicare Physician Payment Proposal

CMS proposed a 2.4% Medicare payment increase for hospitals’ outpatient departments and ambulatory surgery centers in 2026, along with a new two-tiered physician reimbursement structure based on participation in value-based care models. Provider groups are welcoming the short-term boosts, but they fear the changes don’t go far enough to address their long-term financial pressures. The…

Read More